M. A. Cenci

TL;DR: Rats sustaining unilateral near‐complete 6‐hydroxydopamine lesions of the mesostriatal dopamine pathway received daily injections of 3,4 dihydroxyphenyl‐l‐alanine (L‐DOPA, 8 mg/kg plus 15mg/kg benserazide) for 3 weeks and gradually developed abnormal involuntary movements.

TL;DR: It is demonstrated that 6‐OHDA‐lesioned rats do exhibit motor deficits that share essential functional similarities with parkinsonian akinesia or dyskinesia, and can be quantified using novel and relatively simple testing procedures, whereas rotometry cannot discriminate between dyskinetic and antiakinetic effects of antiparkinsonian treatments.

TL;DR: The present results show that L-DOPA administration produces a long-lasting increase in the levels of FosB-, but not JunB-like immunoreactivity in the dopamine-denervated striatum, and exhibits both regional and compartmental specificity.

TL;DR: The present data provide the first demonstration that l‐DOPA maintains high striatal levels of fosB and prodynorphin gene expression during a prolonged course of treatment, which simulates the clinical practice in Parkinson's disease more closely than the short‐treatment paradigms studied thus far.

TL;DR: It is shown thatlevodopa-induced dyskinesia in hemiparkinsonian rats is strongly associated with pronounced 80 Hz local field potential oscillations in the primary motor cortex following levodopa treatment, and this mechanism may also play a role in several other psychiatric and neurological conditions involving cortical dysfunction.